KIVU-107 for Cancer

This trial tests a new treatment called KIVU-107, a potential cancer therapy, to determine its safety and tolerability for individuals with advanced or metastatic solid tumors. These tumors have spread and do not respond to standard treatments. The trial consists of two parts: the first part explores different doses of KIVU-107, while the second part uses the most effective dose identified. Individuals whose cancer has not improved with existing therapies and who have good organ function may be suitable for this study. Participants should not have undergone specific previous cancer treatments or have certain health conditions, such as uncontrolled heart disease. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial information does not specify if you need to stop taking your current medications. However, it mentions that you should not have had major surgery, radiation therapy, or systemic anti-cancer treatment within 3 weeks before starting the study.

Research has shown that KIVU-107 has a promising safety record in early studies. These studies, often using animals or lab models, found that KIVU-107 has strong anti-tumor effects and was generally well-tolerated. This suggests that KIVU-107 might be safe for humans. However, as this is a Phase 1 trial, it marks the first time KIVU-107 is tested in people. The trial's main goal is to assess its safety for humans. Researchers will closely monitor participants' reactions and any possible side effects.¹²³⁴⁵

KIVU-107 is unique because it targets cancer in a novel way by using a new active ingredient that is different from the typical chemotherapy or radiation therapies. Most treatments for cancer, like chemotherapy, work by attacking rapidly dividing cells, which can also harm healthy cells. However, KIVU-107 is designed to specifically target cancer cells with less impact on normal cells, potentially reducing side effects. Researchers are excited about this treatment because it offers a new approach to attacking cancer cells, which could improve effectiveness and patient quality of life. Additionally, the dose-finding and expansion approach in its clinical trial suggests a tailored treatment strategy, aiming for optimal dosing with maximum benefits and minimal risks.

Research has shown that KIVU-107 effectively fights tumors in early lab studies. This treatment is a specialized drug targeting a protein commonly found in cancer cells. In these studies, KIVU-107 demonstrated strong tumor-fighting abilities and maintained a good safety record. This trial will focus on KIVU-107 alone, with participants in the Dose Finding arm receiving multiple ascending doses to determine the optimal dose. The Dose Expansion arm will then treat participants with the recommended dose established in the Dose Finding arm. These encouraging results suggest that KIVU-107 could be useful in treating solid tumors.¹²⁶⁷⁸